Gilead Sciences announced that the National Medical Products Administration (NMPA) has approved Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) in China...
Read moreStem Cell Medicine Ltd. (SCM), a biotechnology company developing new therapies for neurological indications, including mesenchymal stem cells and anti-BMP...
Read moreBristol-Myers Squibb Company and Celgene Corporation announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb...
Read moreNuvo Pharmaceuticals has acquired the rights covering more than 20 drugs from fellow Canadian company Aralez Pharmaceuticals. With the deal,...
Read moreBritish pharmaceutical company Mereo BioPharma Group has announced a proposal to merge with US-based drugmaker OncoMed Pharmaceuticals. The integrated business...
Read moreIQVIA announced that Napo Pharmaceuticals, Inc. (Napo), a wholly-owned subsidiary of Jaguar Health, Inc., has selected Orchestrated Customer Engagement (OCE),...
Read moreBluebird bio, Inc. and Celgene Corporation announced initial data from the ongoing Phase 1 clinical study of bb21217 (CRB-402), an...
Read moreCelltrion, Inc. announced that the EMA has accepted for review of the Extension Marketing Authorisation Application for ‘Remsima SC’, the...
Read moreQPS, a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development, announced the expansion of its U.S.-based...
Read moreShire plc the leading global biotechnology company focused on rare diseases, announced that the European Commission (EC) has granted Marketing...
Read morePharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
© 2017 Copyright © Valuemediaservices 2017 All rights reserved.
Notifications